# A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants

> **NCT05827874** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Nipocalimab
- **BIOLOGICAL:** Tdap
- **BIOLOGICAL:** PPSV23

## Key facts

- **NCT ID:** NCT05827874
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-12
- **Primary completion:** 2023-10-04
- **Final completion:** 2023-10-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05827874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05827874, "A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05827874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*